1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine dihydrochloride

그림문자(GHS)

• 그림문자(GHS)

  

• 신호 어

  Warning

• 유해·위험 문구

  H315：피부에 자극을 일으킴

  H319：눈에 심한 자극을 일으킴

  H335：호흡 자극성을 일으킬 수 있음

• 예방조치문구

  P264：취급 후에는 손을 철저히 씻으시오.

  P264：취급 후에는 손을 철저히 씻으시오.

  P280：보호장갑/보호의/보안경/안면보호구를 착용하시오.

  P302+P352：피부에 묻으면 다량의 물로 씻으시오.

  P305+P351+P338：눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.

  P321：(…) 처치를 하시오.

  P332+P313：피부 자극이 생기면 의학적인 조치· 조언을 구하시오.

  P362：오염된 의복을 벗고 세척 후에 재사용하기

1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine dihydrochloride 화학적 특성, 용도, 생산

• 용도

  1-{[2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazine Dihydrochloride is an intermediate used in the preparation of Venetoclax (A112430), which is a potent and selective BCL-2 inhibitor with potent antitumour activity while sparing platelets. Venetoclax is used to treat chronic lymphocytic leukaemic cells and estrogen receptor-positive breast cancer.

• Synthesis

  To a solution of tert-butyl 4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazine-1 - carboxylate 6 (30 g, 0.072 mol) in MeOH (20 mL) was added conc.HCI (50 mL). The reaction was stirred for 24 hours and then concentrated under reduced pressure. A saturated solution of NazCCh was added to adjust the pH to 8-9, and the mixture was extracted with dichloromethane (2x200 mL). The combined extracts were washed with brine, dried (NazSC ), filtered, and concentrated under reduced pressure. The oil product was treated with MeOH/HCI (g) (3.0 M, 500 mL) and stirred for 1 hour, then concentrated under reduced pressure to get the product 1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine dihydrochloride (23 g, 83%).
  

1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine dihydrochloride 공급 업체

Global(178)Suppliers